{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T10:47:18Z","timestamp":1773312438697,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007136","name":"Karyopharm Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007136","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.clml.2023.06.001","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T19:52:42Z","timestamp":1685994762000},"page":"e286-e296.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies"],"prefix":"10.1016","volume":"23","author":[{"given":"Gary J.","family":"Schiller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brea C.","family":"Lipe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nizar J.","family":"Bahlis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sascha A.","family":"Tuchman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William I.","family":"Bensinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather J.","family":"Sutherland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1708-7344","authenticated-orcid":false,"given":"Suzanne","family":"Lentzsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhamed","family":"Baljevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1341-4160","authenticated-orcid":false,"given":"Darrell","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rami","family":"Kotb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine I.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9914-5628","authenticated-orcid":false,"given":"Adriana","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noa","family":"Biran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9990-2183","authenticated-orcid":false,"given":"Richard","family":"LeBlanc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2644-1050","authenticated-orcid":false,"given":"Sebastian","family":"Grosicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Martelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1327-2921","authenticated-orcid":false,"given":"Eberhard","family":"Gunsilius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"\u0160pi\u010dka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don Ambrose","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Facon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes Gironella","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dane R.","family":"Van Domelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ohad S.","family":"Bentur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Gasparetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.clml.2023.06.001_bib0001","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2017-05-743203","article-title":"How I treat myeloma with new agents","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2023.06.001_bib0002","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","article-title":"Clonal competition with alternating dominance in multiple myeloma","volume":"120","author":"Keats","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2023.06.001_bib0003","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1038\/s41375-018-0153-6","article-title":"Multiple myeloma clonal evolution in homogeneously treated patients","volume":"32","author":"Corre","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2023.06.001_bib0004","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.06.001_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/ph14010020","article-title":"The role of monoclonal antibodies in the first-line treatment of transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"14","author":"Bonello","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"10.1016\/j.clml.2023.06.001_bib0006","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/17474086.2020.1753502","article-title":"Monoclonal antibodies in newly diagnosed and smoldering multiple myeloma: an updated review of current clinical evidence","volume":"13","author":"Musto","year":"2020","journal-title":"Expert Rev Hematol"},{"issue":"9","key":"10.1016\/j.clml.2023.06.001_bib0007","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.clml.2023.06.001_bib0008","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.06.001_bib0009","unstructured":"Mehra M, Vogel M, Valluri S, et\u00a0al. Patient characteristics, treatment patterns and outcomes in patients with triple class refractory multiple myeloma. European Haematology Association (EHA) Library 2020;(Abstract release date: 05\/14\/20) 293522; EP1032."},{"issue":"1","key":"10.1016\/j.clml.2023.06.001_bib0010","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/leu.2013.115","article-title":"CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications","volume":"28","author":"Tai","year":"2014","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.clml.2023.06.001_bib0011","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2023.06.001_bib0012","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/jha2.120","article-title":"Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myeloma","volume":"2","author":"Richardson","year":"2021","journal-title":"eJHaem"},{"issue":"1","key":"10.1016\/j.clml.2023.06.001_bib0013","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.1002\/ajh.26010","article-title":"Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH","volume":"96","author":"Cornell","year":"2021","journal-title":"Am J Hematol"},{"issue":"10262","key":"10.1016\/j.clml.2023.06.001_bib0014","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2023.06.001_bib0015","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-148759","article-title":"Once weekly oral selinexor, pomalidomide, and dexamethasone in relapsed refractory multiple myeloma","volume":"138","author":"White","year":"2021","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.clml.2023.06.001_bib0016","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1182\/blood-2018-06-858852","article-title":"Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma","volume":"132","author":"Bahlis","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2023.06.001_bib0017","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/s41416-021-01608-2","article-title":"Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients","volume":"126","author":"Gasparetto","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2023.06.001_bib0018","series-title":"European School of Hematology (ESH) 2nd International Conference on Multiple Myeloma Athens","article-title":"In vitro and in vivo anti-multiple myeloma activity of selinexor (KPT-330), an oral selective inhibitor of nuclear export (SINE) compound, is enhanced through combination with standard anti-myeloma agents","author":"Carlson","year":"2014"},{"issue":"48","key":"10.1016\/j.clml.2023.06.001_bib0019","doi-asserted-by":"crossref","first-page":"78896","DOI":"10.18632\/oncotarget.12969","article-title":"XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IkappaBalpha and overcomes acquired proteasome inhibitor resistance in human multiple myeloma","volume":"7","author":"Turner","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2023.06.001_bib0020","article-title":"Rationale for Selinexor Treatment in Daratumumab-Refractory MM Patients Identified By Paired Ex Vivo Drug Sensitivity and RNA-Seq","author":"Sudalagunta","year":"2021","journal-title":"American Society of Hematology (ASH) Congress"},{"issue":"8","key":"10.1016\/j.clml.2023.06.001_bib0021","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clml.2023.06.001_bib0022","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Annals of Oncology"},{"issue":"7","key":"10.1016\/j.clml.2023.06.001_bib0023","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.3390\/cancers13071686","article-title":"Emerging therapeutic strategies to overcome drug resistance in multiple myeloma","volume":"13","author":"Davis","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.clml.2023.06.001_bib0024","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10245","key":"10.1016\/j.clml.2023.06.001_bib0025","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2023.06.001_bib0026","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1182\/blood-2020-135874","article-title":"Apollo: phase 3 randomized study of subcutaneous daratumumab plus pomalidomide and dexamethasone (D-Pd) versus pomalidomide and dexamethasone (Pd) alone in patients (Pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"136","author":"Dimopoulos","year":"2020","journal-title":"Blood"},{"issue":"10214","key":"10.1016\/j.clml.2023.06.001_bib0027","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"issue":"10292","key":"10.1016\/j.clml.2023.06.001_bib0028","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.clml.2023.06.001_bib0029","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.tranon.2017.04.010","article-title":"Selinexor overcomes hypoxia-induced drug resistance in multiple myeloma","volume":"10","author":"Muz","year":"2017","journal-title":"Transl Oncol"},{"issue":"1","key":"10.1016\/j.clml.2023.06.001_bib0030","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1158\/1535-7163.MCT-15-0488","article-title":"Synergistic myeloma cell death via novel intracellular activation of caspase-10-dependent apoptosis by carfilzomib and selinexor","volume":"15","author":"Rosebeck","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2023.06.001_bib0031","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720930629","article-title":"Selinexor in relapsed\/refractory multiple myeloma","volume":"11","author":"Richter","year":"2020","journal-title":"Ther Adv Hematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023001842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023001842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:43:16Z","timestamp":1761871396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023001842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S2152265023001842"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.06.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}